TABLE 2.
Patient demographics and clinical characteristics at baseline by initial MMD response status at Month 1
| Erenumab 70 mg (N = 188) | Erenumab 140 mg (N = 187) | |||||
|---|---|---|---|---|---|---|
| Responders (N = 45) | Partial responders (N = 45) | Nonresponders (N = 98) | Responders (N = 53) | Partial responders (N = 34) | Nonresponders (N = 100) | |
| Age, years | 40.8 (9.9) | 41.8 (11.8) | 41.0 (11.7) | 43.1 (10.8) | 46.3 (7.8) | 42.0 (11.9) |
| Female, n (%) | 42 (93.3) | 39 (86.7) | 84 (85.7) | 45 (84.9) | 31 (91.2) | 83 (83.0) |
| Disease duration, years | 20.1 (12.3) | 20.7 (11.3) | 20.3 (13.4) | 22.0 (11.8) | 23.1 (10.8) | 21.8 (12.2) |
| History of previous prevention treatment failure, n (%) | ||||||
| Failure of ≥1 category | 28 (62.2) | 27 (60.0) | 69 (70.4) | 32 (60.4) | 25 (73.5) | 68 (68.0) |
| Failure of ≥2 categories | 18 (40.0) | 21 (46.7) | 52 (53.1) | 24 (45.3) | 17 (50.0) | 52 (52.0) |
| Previous use of preventives, n (%) | ||||||
| Topiramate | 16 (35.6) | 21 (46.7) | 50 (51.0) | 26 (49.1) | 20 (58.8) | 51 (51.0) |
| OnabotulinumtoxinA | 9 (20.0) | 10 (22.2) | 29 (29.6) | 9 (17.0) | 6 (17.6) | 28 (28.0) |
| Headache characteristics during the baseline period | ||||||
| Monthly headache days | 19.4 (3.1) | 20.3 (3.5) | 21.3 (4.0) | 20.1 (3.5) | 20.5 (3.1) | 21.2 (4.0) |
| MMD | 16.2 (3.6) | 17.6 (3.5) | 18.9 (4.8) | 17.0 (4.5) | 17.7 (4.0) | 18.2 (5.0) |
| Monthly AMSM days | 7.5 (7.0) | 9.8 (7.0) | 8.9 (7.4) | 9.6 (7.2) | 11.2 (6.5) | 9.2 (7.1) |
| AMSM use, n (%) | 28 (62.2) | 35 (77.8) | 77 (78.6) | 39 (73.6) | 31 (91.2) | 77 (77.0) |
| Monthly AMSM days among AMSM users | 12.0 (4.7) | 12.6 (5.2) | 11.3 (6.5) | 13.1 (5.0) | 12.3 (5.7) | 11.9 (5.7) |
Data are mean (SD), unless otherwise stated.
Abbreviations: AMSM, acute migraine‐specific medication; MMD, monthly migraine day.